Table 4. Multivariate analysis of factors relating to successful engraftment of PDX models.
| Factors | p-value | OR | 95% C.I. | |
|---|---|---|---|---|
|
All cases (n = 83) |
Histologic grade (I/II vs. III) | 0.004 | 7.040 | 1.847–26.836 |
| BRCA mutation (absent vs. present) | 0.012 | 7.262 | 1.549–34.034 | |
| Survival status (live vs. Death) | 0.021 | 8.247 | 1.382–49.444 | |
| Aggressive diseases (absent vs. present) | 0.006 | 4.860 | 1.577–14.974 | |
|
TNBC cases (n = 65) |
Histologic grade (I/II vs. III) | 0.034 | 4.406 | 1.114–17.420 |
| BRCA mutation (absent vs. present) | 0.039 | 5.119 | 1.083–24.196 | |
| Survival status (live vs. Death) | 0.053 | 5.867 | 0.974–35.339 | |
| Aggressive diseases (absent vs. present) | 0.027 | 3.700 | 1.162–11.783 | |
|
Neo TNBC cases (n = 39) |
Histologic grade (I/II vs. III) | 0.030 | 11.636 | 1.269–106.719 |
| BRCA mutation (absent vs. present) | 0.056 | 7.000 | 0.952–51.448 | |
| Survival status (live vs. Death) | 0.056 | 7.000 | 0.952-51-448 | |
| Aggressive diseases (absent vs. present) | 0.007 | 11.500 | 1.930–68.518 |